Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

mylan institutional llc - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml

Israel - engleză - Ministry of Health

sanofi israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - clexane is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Israel - engleză - Ministry of Health

sanofi - aventis israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin - clexane forte is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary inte

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -